(Corrects typo in headline)
Oct 30 (Reuters) - Regeneron Pharmaceuticals said on Friday an independent data monitoring panel recommended placing on hold enrolment to its trial for COVID-19 antibody treatment in hospitalized patients requiring high-flow oxygen or mechanical ventilation.
The committee, however, backed the enrolment in non-hospitalized patients as well as hospitalized patients requiring either no or low-flow oxygen. (Reporting by Ankur Banerjee in Bengaluru; Editing by Arun Koyyur)
Our Standards: The Thomson Reuters Trust Principles.